Patents Assigned to Pharmacia Corporation
-
Publication number: 20140141079Abstract: An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: Pharmacia CorporationInventors: Ernest J. Lee, Gerard M. Bredael, John R. Baldwin, Steven R. Cox, Mark J. Heintz
-
Patent number: 8679533Abstract: An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.Type: GrantFiled: July 24, 2003Date of Patent: March 25, 2014Assignee: Pharmacia CorporationInventors: Ernest J. Lee, Gerard M. Bredael, John R. Baldwin, Steven R. Cox, Mark J. Heintz
-
Patent number: 8338374Abstract: The present invention is directed to stable liquid growth hormone formulations that remain stable after physical agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temperatures, even frozen. In the present invention, a combination of buffer and stabilizing agents, including a non-ionic surfactant (e.g., polysorbate 20), a polymer stabilizer (e.g., polyethylene glycol), and other optional stabilizers combine to provide unexpected stability to aqueous formulations of a growth hormone (e.g., human growth hormone).Type: GrantFiled: December 13, 2004Date of Patent: December 25, 2012Assignee: Pharmacia CorporationInventors: Manpreet S Wadhwa, Sandeep Nema, Advait Badkar
-
Patent number: 7795271Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.Type: GrantFiled: May 4, 2009Date of Patent: September 14, 2010Assignee: Pharmacia CorporationInventor: Richard C. Durley
-
Patent number: 7445641Abstract: The present invention relates to biomaterials modified with non-proteinaceous catalysts for the dismutation of superoxide, and processes for making such materials. This modification may be by covalent conjugation, copolymerization, or admixture of the non-proteinaceous catalysts with the biomaterial. The resulting modified biomaterials exhibit a marked decrease in inflammatory response and subsequent degradation when placed in contact with vertebrate biological systems.Type: GrantFiled: May 26, 2000Date of Patent: November 4, 2008Assignee: Pharmacia CorporationInventors: Richard Ornberg, Kishore Udipi, Denis Forster, Dennis Riley, Bruce Thurmond, Susan Henke, Kerry Brethauer
-
Patent number: 7420061Abstract: Prodrugs of COX-2 inhibitors are described as being useful in treating inflammation and inflammation-related disorders.Type: GrantFiled: September 13, 2004Date of Patent: September 2, 2008Assignee: Pharmacia CorporationInventors: John J. Talley, James W. Malecha, Stephen Bertenshaw, Matthew J. Graneto, Jeffery S. Carter, Jinglin Li, Srinivasan R. Nagarajan, David L. Brown, Donald J. Rogier, Jr., Thomas D. Penning, Ish K. Khanna, Xiangdong Xu, Richard M. Weier
-
Publication number: 20080153894Abstract: A method is provided for treatment of an infective condition in an udder of a milk producing animal. The method comprises intramammary administration of an antibacterial agent in combination therapy with a selective COX-2 inhibitor in therapeutically effective amounts of each. Also provided is a pharmaceutical composition comprising an antibacterial agent and a selective COX-2 inhibitor, together with one or more excipients, in a dosage form suitable for intramammary administration to a milk producing animal.Type: ApplicationFiled: February 26, 2008Publication date: June 26, 2008Applicant: PHARMACIA CORPORATIONInventors: Nancy J. Britten, John W. Hallberg, Niki A. Waldron, Jeffrey L. Watts
-
Publication number: 20080103311Abstract: N-heterocyclic moiety containing hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.Type: ApplicationFiled: December 11, 2007Publication date: May 1, 2008Applicant: Pharmacia CorporationInventors: John Tally, Daniel Getman, Gary DeCrescenzo, Kathryn Reed, Ko-Chung Lin, John Freskos, Michael Clare, Donald Rogier, Robert Heintz, Michael Vazquez, Richard Mueller
-
Patent number: 7320996Abstract: The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors of the formula I: wherein R1, R2, R3, R4, R5, R6, and R7 are defined herein, in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.Type: GrantFiled: August 15, 2002Date of Patent: January 22, 2008Assignees: Sugen, Inc, Pharmacia CorporationInventors: Jaime Masferrer, Parul Doshi, Julie Cherrington
-
Patent number: 7312333Abstract: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.Type: GrantFiled: January 13, 2006Date of Patent: December 25, 2007Assignee: Pharmacia CorporationInventors: John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, Kathryn L. Reed, Ko-Chung Lin, John N. Freskos, Michael Clare, Donald J. Rogier, Jr., Robert M. Heintz, Michael L. Vazquez, Richard A. Mueller
-
Patent number: 7259266Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.Type: GrantFiled: March 16, 2004Date of Patent: August 21, 2007Assignee: Pharmacia CorporationInventors: Jeffry Carter, David Brown, Li Xing, Karl Aston, John Springer, Francis Koszyk, Steven Kramer, Renee Huff, Yi Yu, Bruce Hamper, Subo Laio, Angela Deprow, Teresa Fletcher, E. Ann Hallinan, James Kiefer, David Limburg, Lijuan Wang, Cindy Ludwig, John McCall, John Talley
-
Publication number: 20070167621Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.Type: ApplicationFiled: July 14, 2006Publication date: July 19, 2007Applicant: PHARMACIA CORPORATIONInventor: Richard Durley
-
Patent number: 7238507Abstract: The present invention relates to a novel cytochrome P450-like enzyme (Aspergillus ochraceus 11 alpha hydroxylase) and an oxidoreductase (Aspergillus ochraceus oxidoreductase) isolated from cDNA library generated from the mRNA of Aspergillus ochraceus spores. When the cDNA encoding the 11 alpha hydroxylase was co-expressed in Spodoptera frugiperda (Sf-9) insect cells with the cDNA encoding human oxidoreductase as an electron donor, it successfully catalyzed the conversion of the steroid substrate 4-androstene-3,17-dione (AD) to 11 alpha-hydroxy-AD as determined by HPLC analysis. The invention also relates to nucleic acid molecules associated with or derived from these cDNAs including complements, homologues and fragments thereof, and methods of using these nucleic acid molecules, to generate, for example, polypeptides and fragments thereof. The invention also relates to the generation of antibodies that recognizes the A.Type: GrantFiled: July 28, 2004Date of Patent: July 3, 2007Assignee: Pharmacia CorporationInventors: Suzanne L. Bolten, Robert A. Clayton, Alan M. Easton, Leslie C. Engel, Dean M. Messing, John S. Ng, Beverly Reitz, Mark C. Walker, Ping T. Wang
-
Patent number: 7220867Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.Type: GrantFiled: July 26, 2005Date of Patent: May 22, 2007Assignee: Pharmacia Corporation (of Pfizer, Inc.)Inventors: Michael J. Hageman, Xiaorong He, Tugrul T. Kararli, Lesley A. MacKin, Patricia J. Miyake, Brian R. Rohrs, Kevin J. Stefanski
-
Patent number: 7220434Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.Type: GrantFiled: December 20, 2000Date of Patent: May 22, 2007Assignee: Pharmacia Corporation (of Pfizer, Inc.)Inventors: Subhash Desai, Sreekant R. Nadkarni, Randy J. Wald, Gary A. DeBrincat
-
Patent number: 7211686Abstract: The invention includes selected novel optically active ?-amino ketones which either are themselves useful or are intermediates for the preparation of known ketomethylene pseudopeptides useful as antibiotics, antibiotic enhancers, or enzyme inhibitors. Further, the present invention provides a method for dehydrogenation/asymmetrical hydrogenation to obtain essentially pure antipodes of ketomethylene pseudopeptides having two chiral centers.Type: GrantFiled: January 12, 2005Date of Patent: May 1, 2007Assignee: Pharmacia CorporationInventor: John J. Talley
-
Patent number: 7196118Abstract: The present invention relates to amidino compounds and salts and prodrugs thereof. In another embodiment the present invention also provides a use of the present compounds in therapy, particular as nitric oxide synthase inhibitors. In a further embodiment, the present invention provides methods of making the amidino compounds.Type: GrantFiled: January 10, 2005Date of Patent: March 27, 2007Assignee: Pharmacia CorporationInventors: Ronald Keith Webber, Richard C. Durley, Alok K. Awasthi, Arija A. Bergmanis, Kam F. Fok, Scott S. Ganser, Timothy J. Hagen, E. Ann Hallinan, Donald W. Hansen, Jr., Brian S. Hickory, Pamela T. Manning, Michael Mao, Alan E. Moormann, Barnett S. Pitzele, Michelle A. Promo, Richard R. Schartman, Jeffrey A. Scholten, Jeffrey S. Snyder, Mihaly V. Toth, Mahima Trivedi, Sofya Tsymbalov, Foe Siong Tjoeng
-
Patent number: 7186743Abstract: The present invention relates to substituted pyrazolyl derivatives, compositions comprising such, intermediates, methods of making substituted pyrazolyl derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.Type: GrantFiled: April 25, 2005Date of Patent: March 6, 2007Assignee: Pharmacia CorporationInventors: Arija A. Bergmanis, Michael Clare, Joyce Z. Crich, Lifeng Geng, Timothy J. Hagen, Gunnar J. Hanson, Stephen C. Houdek, He Huang, Donna M. Iula, Francis J. Koszyk, Shuyuan Liao, Scott B. Mohler, Maria Nguyen, Richard A. Partis, Michael A. Stealey, Michael B. Tollefson, Richard M. Weier, Xiangdong Xu, Dominique Bonafoux, Theresa R. Fletcher, Bruce C Hamper, Patrick J. Lennon, Subo Liao, Suzanne Metz, David S. Oburn, Thomas J. Owen, Angela M. Scates, Michael L. Vazquez, Serge G. Wolfson
-
Patent number: 7183287Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.Type: GrantFiled: March 24, 2004Date of Patent: February 27, 2007Assignee: Pharmacia CorporationInventor: Richard C Durley
-
Patent number: 7172769Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particle, about 25% to 100% by weight of which are smaller than 1 ?m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.Type: GrantFiled: December 6, 2000Date of Patent: February 6, 2007Assignee: Pharmacia CorporationInventors: Tugrul T. Kararli, Mark J. Kontny, Subhash Desai, Michael J. Hageman, Royal J. Haskell